DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: ZEMPLAR

Summary for Tradename: ZEMPLAR

Patents:4
Applicants:1
NDAs:2
Suppliers: see list3
drug
patent expirations by year for
 ZEMPLAR

Pharmacology for Tradename: ZEMPLAR

Ingredient-typeCholecalciferol
Drug ClassVitamin D3 Analog

Clinical Trials for: ZEMPLAR

The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
Status: Completed Condition: Diabetic Nephropathy; Chronic Kidney Disease

Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation
Status: Completed Condition: Chronic Kidney Disease; Endothelial Dysfunction; Inflammation; Hypertension

Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis
Status: Completed Condition: Secondary Hyperparathyroidism; Dialysis

The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate
Status: Completed Condition: Chronic Kidney Disease

Oral Paricalcitol in Kidney Transplant Recipients
Status: Completed Condition: Transplant; Failure, Kidney; Renal Disease, End Stage; Hyperparathyroidism, Secondary

Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D
Status: Completed Condition: Chronic Kidney Disease; Secondary Hyperparathyroidism; Hemodialysis

Study of Zemplar iv in Patients With End Stage Chronic Kidney Disease, Undergoing Haemodialysis
Status: Completed Condition: Parathyroid Hormone

Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis
Status: Completed Condition: Chronic Kidney Disease on Hemodialysis; Secondary Hyperparathyroidism

Effect Of Paricalcitol (Zemplar) On Endothelial Function And Inflammation In Type 2 Diabetes And Chronic Kidney Disease
Status: Active, not recruiting Condition: Type 2 Diabetes; Chronic Kidney Disease

Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery
Status: Active, not recruiting Condition: Mucinous Adenocarcinoma of the Rectum; Stage IIA Rectal Cancer; Stage IIB Rectal Cancer; Stage IIC Rectal Cancer; Stage IIIB Rectal Cancer; Stage IIIC Rectal Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606May 26, 2005RXNo5,587,497*PED<disabled>Y<disabled>
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606May 26, 2005RXNo5,597,815*PED<disabled>Y<disabled>
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606May 26, 2005RXYes5,587,497*PED<disabled>Y<disabled>
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606May 26, 2005RXYes5,597,815*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ZEMPLAR

Drugname Dosage Strength RLD Submissiondate
paricalcitolInjection0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vialsZemplar11/28/2008
paricalcitolCapsules1 mcg and 2 mcgZemplar10/14/2008
paricalcitolCapsules4 mcgZemplar8/25/2008

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc